APP and Alzheimer disease: In this regard, the inhibition of DYRK1A activity may synergistically improve cognition and reduce the formation of Aβ oligomers through inhibition of APP phosphorylation, while also reducing AD-associated tau hyperphosphorylation and pathology through inhibition of tau phosphorylation and regulation of tau E10 inclusion.